Enanta Pharmaceuticals (ENTA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Enanta Pharmaceuticals (ENTA) is Neutral.

The composite score behind that read is -0.06, weighing +0.04 of bullish evidence against -0.28 bearish.

Enanta Pharmaceuticals last closed at $12.50, +3.31% on the session.

Against the IVW growth benchmark the position is +2.51% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

20 graded predictions for ENTA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Enanta Pharmaceuticals in the 16th percentile on return on equity, where 100 is best.

Enanta Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $352.41M.

StockMap tracks Enanta Pharmaceuticals as the 202nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Enanta Pharmaceuticals ranks 157th of 381 in the group, against a group median of -0.08.